Muhammad Umair Mushtaq
Overview
Explore the profile of Muhammad Umair Mushtaq including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
558
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Shahzad M, Khalid M, Amin M, Ammad-Ud-Din M, Ilyas U, Mushtaq A, et al.
Hematol Oncol Stem Cell Ther
. 2024 Apr;
17(2):88-94.
PMID: 38560970
This systematic review aimed to evaluate the proportion of primary and secondary endpoints in hematopoietic stem cell transplant (HSCT) phase III randomized clinical trials (RCTs) and analyze their trends in...
12.
McGuirk M, Shahzad M, Amin M, Khan M, Bellman P, Mudaranthakam D, et al.
Transpl Immunol
. 2024 Mar;
84:102039.
PMID: 38513813
Background: We aimed to investigate factors associated with cytomegalovirus (CMV) viremia and CMV disease and its impact on post-transplant outcomes including overall survival (OS) following allogeneic hematopoietic stem cell transplantation...
13.
Shahzad M, Iqbal Q, Tariq E, Ammad-Ud-Din M, Butt A, Mushtaq A, et al.
Crit Rev Oncol Hematol
. 2024 Feb;
196:104310.
PMID: 38423375
We conducted a systematic review and meta-analysis to evaluate outcomes after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) in TP53-mutated myelodysplastic syndromes (MDS). A literature search was performed on PubMed, Cochrane,...
14.
Mushtaq M, Shahzad M, Amin M, Lutfi F, DeJarnette S, Al-Ramahi J, et al.
Leuk Lymphoma
. 2024 Jan;
65(4):493-502.
PMID: 38164945
We investigated the outcomes after adult haploidentical (haplo) and matched unrelated donor (MUD) hematopoietic cell transplantation (HCT) in a single-center study ( = 452) including 276 MUD and 176 haplo...
15.
Al-Ramahi J, Shahzad M, Nguyen A, Li K, Amin M, Ahmed N, et al.
Bone Marrow Transplant
. 2023 Oct;
59(1):134-137.
PMID: 37833526
No abstract available.
16.
Ahmed N, Wesson W, Mushtaq M, Bansal R, Abdelhakim H, Bromert S, et al.
Front Oncol
. 2023 Aug;
13:1206715.
PMID: 37601685
Background: The first-in-class approved BCMA CAR-T therapy was idecabtagene vicleucel (ide-cel), approved in March 2021, for RRMM patients who progressed after 4 or more lines of therapy. Despite the promising...
17.
Al-Ramahi J, Shahzad M, Li K, DeJarnette S, Chaudhary S, Lutfi F, et al.
Leuk Lymphoma
. 2023 Aug;
64(12):1981-1991.
PMID: 37574842
We investigated the outcomes after Coronavirus disease 2019 (COVID) in hematopoietic cell transplant (HCT) or chimeric antigen receptor-T cell (CART) therapy recipients in a single-centre study including all ( = ...
18.
Lutfi F, Goloubeva O, Kowatli A, Gryaznov A, Kim D, Dureja R, et al.
Clin Lymphoma Myeloma Leuk
. 2023 Jul;
23(10):757-763.
PMID: 37453865
CD19 directed CAR-T therapy for Large B-cell lymphoma (LBCL) has shown great therapeutic response in patients with relapsed/refractory disease with response rates of 60-80%. However, in patients with a partial...
19.
Shahzad M, Nguyen A, Hussain A, Ammad-Ud-Din M, Faisal M, Tariq E, et al.
Front Immunol
. 2023 May;
14:1152457.
PMID: 37168849
Background: We conducted a systematic review and meta-analysis to evaluate outcomes following chimeric antigen receptor T cell (CAR-T) therapy in relapsed/refractory acute myeloid leukemia (RR-AML). Methods: We performed a literature...
20.
Ammad Ud Din M, Jaan A, Shahzad M, Liaqat H, McGuirk J, Mushtaq M
Transpl Infect Dis
. 2023 May;
25(3):e14066.
PMID: 37129229
Introduction: Although hospital-acquired influenza infection (HAII) is a known complication among immunocompromised patients, the data in the setting of hospitalization for allogeneic hematopoietic stem cell transplant (allo-HSCT) are scarce. Methods:...